SAILIFE1,591.50

Sai Life Sciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹33,705 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations439.8579.5496.4537.5556.5602.1554.3
Other Income9.19.69.915.38.415.53.5
Total Income448.9589.1506.3552.8564.8617.7557.8
Expenses
+ Cost of Materials Consumed121.5156.9159.5203.5114.2159.2177.9
+ Changes in Inventories-0.710.9-18.4-63.413.72.5-32.9
+ Employee Benefit Expense132.9151.1160.6162.8173.0186.7179.9
+ Finance Costs23.110.912.49.49.77.87.6
+ Depreciation & Amortisation34.137.537.739.744.145.345.9
+ Other Expenses66.3103.173.888.767.777.281.5
Total Expenses377.2470.3425.6440.7422.4478.7459.9
EBITDA119.8157.6120.9145.8187.9176.5148.0
EBIT85.7120.183.2106.1143.8131.2102.1
Profit
PBT before Exceptional Items71.6118.880.7112.1142.5138.998.0
+ Exceptional Items0.00.00.00.0-8.30.30.0
Pretax Income71.6118.880.7112.1134.2139.298.0
+ Current Tax9.917.514.129.731.413.319.7
+ Deferred Tax7.913.06.2-1.42.421.75.0
Tax Expense17.830.520.328.233.835.024.7
Net Income53.988.360.583.8100.4104.273.3
+ Net Income — Continuing Ops53.988.360.583.8100.4104.273.3
+ Other Comprehensive Income-3.97.31.6-14.20.9-9.119.7
Total Comprehensive Income50.095.662.169.6101.395.193.0
Per Share
Basic EPS2.894.242.904.014.774.933.46
Diluted EPS2.844.142.833.934.714.873.42
Other Comprehensive Income — detail
+ Other Comprehensive Income7.31.6-14.20.9-9.119.7
+ Items NOT to be Reclassified to P&L-0.31.3-0.1-0.90.91.60.1
+ Tax on Items NOT to be Reclassified0.3-0.0-0.20.20.40.0
+ Tax on Items NOT to be Reclassified — alt tag-0.1
+ Items to be Reclassified to P&L-5.38.52.2-18.90.1-15.126.2
+ Tax on Items to be Reclassified2.10.5-5.4-0.2-4.86.6
+ Tax on Items to be Reclassified — alt tag-1.7
Per Share — as-filed variants
Basic EPS — Continuing Operations2.894.242.904.014.774.933.46
Diluted EPS — Continuing Operations2.844.142.833.934.714.873.42
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit318.9411.8355.3397.3428.5440.4409.4
Gross Margin %72.5271.0671.5773.9377.0173.1473.86
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)71.6118.880.7112.1142.5138.998.0
− Exceptional Items (reconciliation)0.00.00.00.0-8.30.30.0
Net Income Adj (tax-effected)53.988.360.583.8106.6104.073.3
EPS Adj2.894.242.904.015.064.923.46
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.001.001.001.00
Paid Up Equity Capital20.820.820.921.021.121.221.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.